Histone deacetylase inhibitors (HDACi), including vorinostat/SAHA (pan‐HDAC inhibitor), LBH589/Panobinostat, and EZH2 (Enhancer of zeste homolog 2) inhibitors, for example, tazemetostat, can restore acetylation and reactivate silenced ATGs, restoring autophagy's tumor‐suppressive role in early stages of cancer [43]. Here, EZH2 is linked to cancer.